Chemobrain: Experts Weigh in on Very Real — and Growing — Problem
Major advances in cancer treatment in recent decades have allowed patient survival rates to increase.
Major advances in cancer treatment in recent decades have allowed patient survival rates to increase.
Heron Therapeutics announced that the Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Cinvanti (aprepitant) to expand administration to include a 2-minute intravenous (IV) injection, in addition to the already approved 30-minute IV infusion.
CINV and RINV are a frequent source of misery and distress for patients and ineffective emesis control has well-documented impacts on health-related quality of life.
Patients who receive chemotherapy or radiation therapy are at risk for developing oral mucositis, which causes inflammatory and/or ulcerative lesions of the oral mucosa
Researchers noted that while non-drug costs account for only 7% of CAR-T therapy-related expenses, these costs may range from $30,000 to $56,000.
Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
Management of malignant pleural effusions should be tailored to the particular patient, depending on preference, prognosis, and variety of underlying disease.
As failure to recognize depression symptoms contributes to the association between mortality and depression in cancer patients, early recognition and treatment with pharmacologic and/or psychologic support is essential for improving outcomes.